Wire · opportunities
Samchundang Pharm gains FDA feedback on oral semaglutide generic path
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 July 2026 · Fusion42 review
Samchundang Pharm received FDA Pre-ANDA guidance on its oral semaglutide generic development, reducing regulatory uncertainty though final approval remains subject to subsequent ANDA review. The South Korean manufacturer has already signed supply contracts in the US and Europe and is pursuing regulatory consultations in Japan and the Middle East.
This Wire brief sits within Fusion42's coverage of Digital Health, and 1 source has reported it between 20 Jul 2026 and 26 Jul 2026.
◆ ◆ The Wire takeaway
If you're building the supply chain for GLP-1 generics in the US, Samchundang's cleared pathway tells you the FDA will approve oral semaglutide copies - and a Korean manufacturer is already locking up distribution, meaning you need customers before the price floor collapses. Pre-ANDA guidance is the signal that approval is on track; ANDA filing is imminent.
◆ Coverage
1 source · first reported 20 Jul 2026 · latest 26 Jul 2026
◆ Related on Wire
◆ Topics